{"protocolSection":{"identificationModule":{"nctId":"NCT02145676","orgStudyIdInfo":{"id":"191622-127"},"secondaryIdInfos":[{"id":"2013-002346-37","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Allergan","class":"INDUSTRY"},"briefTitle":"OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity"},"statusModule":{"statusVerifiedDate":"2017-03","overallStatus":"TERMINATED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-05"},"primaryCompletionDateStruct":{"date":"2015-12","type":"ACTUAL"},"completionDateStruct":{"date":"2015-12","type":"ACTUAL"},"studyFirstSubmitDate":"2014-05-21","studyFirstSubmitQcDate":"2014-05-21","studyFirstPostDateStruct":{"date":"2014-05-23","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-12-22","resultsFirstSubmitQcDate":"2016-12-22","resultsFirstPostDateStruct":{"date":"2017-02-14","type":"ACTUAL"},"lastUpdateSubmitDate":"2017-03-14","lastUpdatePostDateStruct":{"date":"2017-04-12","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Allergan","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is a safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper limb spasticity."},"conditionsModule":{"conditions":["Muscle Spasticity","Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":53,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"onabotulinumtoxinA 500U","type":"EXPERIMENTAL","description":"OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1.","interventionNames":["Biological: onabotulinumtoxinA"]},{"label":"onabotulinumtoxinA 300U","type":"EXPERIMENTAL","description":"OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1.","interventionNames":["Biological: onabotulinumtoxinA"]},{"label":"placebo (normal saline)","type":"PLACEBO_COMPARATOR","description":"Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.","interventionNames":["Drug: placebo (normal saline)"]}],"interventions":[{"type":"BIOLOGICAL","name":"onabotulinumtoxinA","description":"OnabotulinumtoxinA injected into predefined muscles of the study limb on Day 1.","armGroupLabels":["onabotulinumtoxinA 300U","onabotulinumtoxinA 500U"],"otherNames":["BOTOXÂ®","botulinum toxin type A"]},{"type":"DRUG","name":"placebo (normal saline)","description":"Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.","armGroupLabels":["placebo (normal saline)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in the Modified Ashworth Scale-Bohannon (MAS-B) Score of Elbow Flexors Using a 6-Point Scale","description":"The MAS-B is a 6-point scale used to evaluate spasticity based on grading the resistance encountered in the elbow flexors by passively moving the elbow flexor muscles through their range of motion. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Scores are converted to a 0 to 5 grade. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.","timeFrame":"Baseline, Week 6"}],"secondaryOutcomes":[{"measure":"Change From Baseline in the MAS-B Score of Shoulder Adductors Using a 6-Point Scale","description":"The MAS-B is a 6-point scale used to evaluate spasticity based on grading the resistance encountered in the shoulder adductors by passively moving the shoulder adductor muscles through their range of motion. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Scores are converted to a 0 to 5 grade. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.","timeFrame":"Baseline, Week 6"},{"measure":"Change From Baseline in Pain on an 11-Point Scale","description":"The patient is asked to select a number that best describes his/her pain in the treated areas of the study limb on an 11-point scale from 0 = \"no pain\" to 10 = \"pain as bad as can be imagined\". Patients are instructed to recall their average pain in the study limb during the 48-hour period prior to the visit. Patients with a baseline pain score \\>0 are included in the analyses. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.","timeFrame":"Baseline, Week 6"},{"measure":"Change From Baseline in the Dressing Domain Score on the Spasticity Impact Assessment-Upper Limb (SIA-UL)","description":"The SIA-UL asks the patient to assess the impact of upper limb spasticity in his/her daily life on a 19-item scale. The scale covers impacts on activities of dressing, showering/bathing, and self-care. The SIA score ranged from 0 (not at all difficult) to 4 (extremely difficult) for each question. The dressing domain was calculated based on the average of 2 questions.","timeFrame":"Baseline, Week 6"},{"measure":"Change From Baseline in the Showering/Bathing Domain Score on the Spasticity Impact Assessment-Upper Limb (SIA-UL)","description":"The SIA-UL asks the patient to assess the impact of upper limb spasticity his/her daily life on a 19-item scale. The scale covers impacts on activities of dressing, showering/bathing, and self-care. The SIA score ranged from 0 (not at all difficult) to 4 (extremely difficult) for each question. The showering/bathing domain was based on a single question.","timeFrame":"Baseline, Week 6"},{"measure":"Change From Baseline in the Self-Care Domain Score on the Spasticity Impact Assessment-Upper Limb (SIA-UL)","description":"The SIA-UL asks the patient to assess the impact of upper limb spasticity in his/her daily life on a 19-item scale. The scale covers impacts on activities of dressing, showering/bathing, and self-care. The SIA score ranged from 0 (not at all difficult) to 4 (extremely difficult) for each question. The self-care domain was calculated based on the average of 4 questions.","timeFrame":"Baseline, Week 6"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Upper limb spasticity in the elbow and shoulder due to stroke, with the most recent stroke at least 3 months ago\n\nExclusion Criteria:\n\n* Spasticity in the non-study upper limb that requires treatment\n* Presence of fixed contractures in of the study muscles in elbow or shoulder\n* Profound atrophy of muscles to be injected\n* Previous surgical intervention, nerve block, or muscle block for the treatment of spasticity in the study limb in the last 12 months\n* Injection of corticosteroids or anesthetics, use of casting or dynamic splinting or constraint-induced movement therapy (CIMT) for the study limb within 3 months\n* Ultrasound therapy, electrical stimulation, or acupuncture in the study limb within 1 month\n* Condition other than stroke contributing to upper limb spasticity\n* Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, and/or amyotrophic lateral sclerosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Allergan","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Overland Park","state":"Kansas","country":"United States","geoPoint":{"lat":38.98223,"lon":-94.67079}},{"city":"Montreal","state":"Quebec","country":"Canada","geoPoint":{"lat":45.50884,"lon":-73.58781}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"onabotulinumtoxinA 500U","description":"OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1."},{"id":"FG001","title":"onabotulinumtoxinA 300U","description":"OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1."},{"id":"FG002","title":"Placebo (Normal Saline)","description":"Placebo (normal saline) injected into predefined muscles of the study limb on Day 1."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"18"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"18"},{"groupId":"FG002","numSubjects":"18"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"onabotulinumtoxinA 500U","description":"OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1."},{"id":"BG001","title":"onabotulinumtoxinA 300U","description":"OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1."},{"id":"BG002","title":"Placebo (Normal Saline)","description":"Placebo (normal saline) injected into predefined muscles of the study limb on Day 1."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"53"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"58.8","spread":"11.46"},{"groupId":"BG001","value":"59.7","spread":"10.36"},{"groupId":"BG002","value":"56.2","spread":"8.30"},{"groupId":"BG003","value":"58.2","spread":"10.01"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"22"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"31"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in the Modified Ashworth Scale-Bohannon (MAS-B) Score of Elbow Flexors Using a 6-Point Scale","description":"The MAS-B is a 6-point scale used to evaluate spasticity based on grading the resistance encountered in the elbow flexors by passively moving the elbow flexor muscles through their range of motion. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Scores are converted to a 0 to 5 grade. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.","populationDescription":"Intent-to-Treat: all randomized patients who were analyzed according to randomization assignment, regardless of treatment actually received","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a Scale","timeFrame":"Baseline, Week 6","groups":[{"id":"OG000","title":"onabotulinumtoxinA 500U","description":"OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1."},{"id":"OG001","title":"onabotulinumtoxinA 300U","description":"OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1."},{"id":"OG002","title":"Placebo (Normal Saline)","description":"Placebo (normal saline) injected into predefined muscles of the study limb on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"18"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.12","spread":"0.332"},{"groupId":"OG001","value":"4.06","spread":"0.236"},{"groupId":"OG002","value":"4.17","spread":"0.383"}]}]},{"title":"Change from Baseline at Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.62","spread":"1.455"},{"groupId":"OG001","value":"-1.47","spread":"1.247"},{"groupId":"OG002","value":"-0.74","spread":"0.970"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the MAS-B Score of Shoulder Adductors Using a 6-Point Scale","description":"The MAS-B is a 6-point scale used to evaluate spasticity based on grading the resistance encountered in the shoulder adductors by passively moving the shoulder adductor muscles through their range of motion. The score ranges from 0 (no increase in muscle tone) to 4 (affected part(s) rigid in flexion or extension). Scores are converted to a 0 to 5 grade. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.","populationDescription":"Intent-to-Treat: all randomized patients who were analyzed according to randomization assignment, regardless of treatment actually received","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a Scale","timeFrame":"Baseline, Week 6","groups":[{"id":"OG000","title":"onabotulinumtoxinA 500U","description":"OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1."},{"id":"OG001","title":"onabotulinumtoxinA 300U","description":"OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1."},{"id":"OG002","title":"Placebo (Normal Saline)","description":"Placebo (normal saline) injected into predefined muscles of the study limb on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"18"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.00","spread":"0.000"},{"groupId":"OG001","value":"4.06","spread":"0.236"},{"groupId":"OG002","value":"4.00","spread":"0.000"}]}]},{"title":"Change from Baseline at Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-1.59","spread":"1.263"},{"groupId":"OG001","value":"-1.39","spread":"1.042"},{"groupId":"OG002","value":"-1.44","spread":"1.004"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Pain on an 11-Point Scale","description":"The patient is asked to select a number that best describes his/her pain in the treated areas of the study limb on an 11-point scale from 0 = \"no pain\" to 10 = \"pain as bad as can be imagined\". Patients are instructed to recall their average pain in the study limb during the 48-hour period prior to the visit. Patients with a baseline pain score \\>0 are included in the analyses. A negative number change from baseline indicates an improvement and a positive number change from baseline indicates a worsening.","populationDescription":"Intent-to-Treat: all randomized patients who were analyzed according to randomization assignment, regardless of treatment actually received","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a Scale","timeFrame":"Baseline, Week 6","groups":[{"id":"OG000","title":"onabotulinumtoxinA 500U","description":"OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1."},{"id":"OG001","title":"onabotulinumtoxinA 300U","description":"OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1."},{"id":"OG002","title":"Placebo (Normal Saline)","description":"Placebo (normal saline) injected into predefined muscles of the study limb on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"13"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.89","spread":"2.714"},{"groupId":"OG001","value":"6.05","spread":"3.197"},{"groupId":"OG002","value":"5.13","spread":"3.586"}]}]},{"title":"Change from Baseline at Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-2.08","spread":"3.585"},{"groupId":"OG001","value":"-2.51","spread":"4.606"},{"groupId":"OG002","value":"-2.64","spread":"3.857"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Dressing Domain Score on the Spasticity Impact Assessment-Upper Limb (SIA-UL)","description":"The SIA-UL asks the patient to assess the impact of upper limb spasticity in his/her daily life on a 19-item scale. The scale covers impacts on activities of dressing, showering/bathing, and self-care. The SIA score ranged from 0 (not at all difficult) to 4 (extremely difficult) for each question. The dressing domain was calculated based on the average of 2 questions.","populationDescription":"Intent-to-Treat: all randomized patients who were analyzed according to randomization assignment, regardless of treatment actually received","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a Scale","timeFrame":"Baseline, Week 6","groups":[{"id":"OG000","title":"onabotulinumtoxinA 500U","description":"OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1."},{"id":"OG001","title":"onabotulinumtoxinA 300U","description":"OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1."},{"id":"OG002","title":"Placebo (Normal Saline)","description":"Placebo (normal saline) injected into predefined muscles of the study limb on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"18"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.61","spread":"1.346"},{"groupId":"OG001","value":"2.91","spread":"1.123"},{"groupId":"OG002","value":"2.82","spread":"1.092"}]}]},{"title":"Change from Baseline at Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.36","spread":"0.854"},{"groupId":"OG001","value":"-0.27","spread":"0.932"},{"groupId":"OG002","value":"-0.55","spread":"1.082"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Showering/Bathing Domain Score on the Spasticity Impact Assessment-Upper Limb (SIA-UL)","description":"The SIA-UL asks the patient to assess the impact of upper limb spasticity his/her daily life on a 19-item scale. The scale covers impacts on activities of dressing, showering/bathing, and self-care. The SIA score ranged from 0 (not at all difficult) to 4 (extremely difficult) for each question. The showering/bathing domain was based on a single question.","populationDescription":"Intent-to-Treat: all randomized patients who were analyzed according to randomization assignment, regardless of treatment actually received","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a Scale","timeFrame":"Baseline, Week 6","groups":[{"id":"OG000","title":"onabotulinumtoxinA 500U","description":"OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1."},{"id":"OG001","title":"onabotulinumtoxinA 300U","description":"OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1."},{"id":"OG002","title":"Placebo (Normal Saline)","description":"Placebo (normal saline) injected into predefined muscles of the study limb on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"18"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.71","spread":"1.231"},{"groupId":"OG001","value":"2.69","spread":"1.263"},{"groupId":"OG002","value":"2.58","spread":"1.188"}]}]},{"title":"Change from Baseline at Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.62","spread":"1.147"},{"groupId":"OG001","value":"-0.36","spread":"1.247"},{"groupId":"OG002","value":"-0.51","spread":"1.064"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Self-Care Domain Score on the Spasticity Impact Assessment-Upper Limb (SIA-UL)","description":"The SIA-UL asks the patient to assess the impact of upper limb spasticity in his/her daily life on a 19-item scale. The scale covers impacts on activities of dressing, showering/bathing, and self-care. The SIA score ranged from 0 (not at all difficult) to 4 (extremely difficult) for each question. The self-care domain was calculated based on the average of 4 questions.","populationDescription":"Intent-to-Treat: all randomized patients who were analyzed according to randomization assignment, regardless of treatment actually received","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Scores on a Scale","timeFrame":"Baseline, Week 6","groups":[{"id":"OG000","title":"onabotulinumtoxinA 500U","description":"OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1."},{"id":"OG001","title":"onabotulinumtoxinA 300U","description":"OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1."},{"id":"OG002","title":"Placebo (Normal Saline)","description":"Placebo (normal saline) injected into predefined muscles of the study limb on Day 1."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"18"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"18"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.58","spread":"1.234"},{"groupId":"OG001","value":"2.61","spread":"1.189"},{"groupId":"OG002","value":"2.61","spread":"1.086"}]}]},{"title":"Change from Baseline at Week 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"0.779"},{"groupId":"OG001","value":"-0.21","spread":"0.667"},{"groupId":"OG002","value":"-0.48","spread":"1.094"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","description":"The Safety Population included all enrolled patients who received a treatment injection. The Safety Population was used to assess adverse events and serious adverse events.","eventGroups":[{"id":"EG000","title":"onabotulinumtoxinA 500U","description":"OnabotulinumtoxinA 500U injected into predefined muscles of the study limb on Day 1.","seriousNumAffected":2,"seriousNumAtRisk":17,"otherNumAffected":4,"otherNumAtRisk":17},{"id":"EG001","title":"onabotulinumtoxinA 300U","description":"OnabotulinumtoxinA 300U injected into predefined muscles of the study limb on Day 1.","seriousNumAffected":0,"seriousNumAtRisk":18,"otherNumAffected":5,"otherNumAtRisk":18},{"id":"EG002","title":"Placebo (Normal Saline)","description":"Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.","seriousNumAffected":3,"seriousNumAtRisk":18,"otherNumAffected":7,"otherNumAtRisk":18}],"seriousEvents":[{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":0,"numAtRisk":18}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA version 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":13},{"groupId":"EG001","numAffected":0,"numAtRisk":10},{"groupId":"EG002","numAffected":0,"numAtRisk":8}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":2,"numAtRisk":18}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":1,"numAtRisk":18}]}],"otherEvents":[{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":17},{"groupId":"EG001","numAffected":1,"numAtRisk":18},{"groupId":"EG002","numAffected":0,"numAtRisk":18}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":0,"numAtRisk":18}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":1,"numAtRisk":18}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":0,"numAtRisk":18}]},{"term":"Electromyogram abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA version 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":0,"numAtRisk":18}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":0,"numAtRisk":18}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":0,"numAtRisk":18}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA version 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":0,"numAtRisk":18}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA version 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":0,"numAtRisk":18}]},{"term":"Sialoadenitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":0,"numAtRisk":18}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":0,"numAtRisk":18}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":1,"numAtRisk":18},{"groupId":"EG002","numAffected":2,"numAtRisk":18}]},{"term":"Arthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":1,"numAtRisk":18},{"groupId":"EG002","numAffected":0,"numAtRisk":18}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":1,"numAtRisk":18},{"groupId":"EG002","numAffected":0,"numAtRisk":18}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":1,"numAtRisk":18},{"groupId":"EG002","numAffected":0,"numAtRisk":18}]},{"term":"Tooth abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":1,"numAtRisk":18},{"groupId":"EG002","numAffected":0,"numAtRisk":18}]},{"term":"Wrist fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":1,"numAtRisk":18},{"groupId":"EG002","numAffected":0,"numAtRisk":18}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA version 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":2,"numAtRisk":18}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA version 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":2,"numAtRisk":18}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":1,"numAtRisk":18}]},{"term":"Head injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA version 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":1,"numAtRisk":18}]},{"term":"Hyperlipidaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA version 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":1,"numAtRisk":18}]},{"term":"Large intestine polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA version 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":1,"numAtRisk":18}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA version 18.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":1,"numAtRisk":18}]},{"term":"Pulmonary function test decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA version 18.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":17},{"groupId":"EG001","numAffected":0,"numAtRisk":18},{"groupId":"EG002","numAffected":1,"numAtRisk":18}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo."},"pointOfContact":{"title":"Therapeutic Area Head,","organization":"Allergan, Inc","email":"clinicaltrials@allergan.com","phone":"714-246-4500"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"}],"ancestors":[{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"},{"id":"D000009422","term":"Nervous System Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Muscle Spasticity","relevance":"HIGH"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001905","term":"Botulinum Toxins"},{"id":"D000019274","term":"Botulinum Toxins, Type A"},{"id":"C000542869","term":"abobotulinumtoxinA"}],"ancestors":[{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M4873","name":"Botulinum Toxins","asFound":"250","relevance":"HIGH"},{"id":"M250157","name":"abobotulinumtoxinA","asFound":"Maintenance therapy","relevance":"HIGH"},{"id":"M20947","name":"Botulinum Toxins, Type A","asFound":"Maintenance therapy","relevance":"HIGH"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":true}